Brokerages Set Revance Therapeutics, Inc. (NASDAQ:RVNC) PT at $8.39

Revance Therapeutics, Inc. (NASDAQ:RVNC) has received an average rating of “Hold” from the nine brokerages that are covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $8.39.

A number of research analysts have weighed in on the stock. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. HC Wainwright reissued a “neutral” rating and set a $6.60 price objective on shares of Revance Therapeutics in a research note on Friday, November 8th. Barclays dropped their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Mizuho reduced their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Finally, StockNews.com initiated coverage on shares of Revance Therapeutics in a report on Sunday. They issued a “hold” rating for the company.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Certuity LLC acquired a new position in shares of Revance Therapeutics in the 2nd quarter worth approximately $26,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Revance Therapeutics in the second quarter valued at approximately $33,000. Hsbc Holdings PLC acquired a new position in Revance Therapeutics during the second quarter worth $38,000. FORA Capital LLC acquired a new position in Revance Therapeutics during the third quarter worth $54,000. Finally, Creative Planning purchased a new position in shares of Revance Therapeutics during the third quarter worth $56,000. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Trading Down 1.7 %

NASDAQ:RVNC opened at $3.41 on Wednesday. The stock has a 50 day moving average of $3.86 and a two-hundred day moving average of $4.51. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $7.59. The firm has a market cap of $355.97 million, a P/E ratio of -1.77 and a beta of 0.86.

Revance Therapeutics (NASDAQ:RVNC) last issued its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million for the quarter, compared to analyst estimates of $67.73 million. On average, research analysts forecast that Revance Therapeutics will post -1.57 earnings per share for the current year.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.